Bristol Myers, AstraZeneca settle PD-1, CTLA-4 cancer immunotherapy patent suits for $510M

Bristol Myers Squibb and AstraZeneca have quickly resolved patent infringement lawsuits around their blockbuster cancer immunotherapies.

A federal judge in Delaware has approved the two companies’ joint stipulations to dismiss three separate lawsuits. In the suits, BMS accused AstraZeneca of encroaching on patents covering its PD-1 inhibitor Opdivo and CTLA-4 agent Yervoy.